Clay Siegall – A Leader In Drug Development and Cancer Treatment

Seattle Genetics is an American Biotech company located in Seattle, Washington. Since its founding in 1998, this company has been dedicated to creating drugs fueled by antibodies. At Seattle Genetics, antibodies are studied and manipulated in order to create these the type of drugs mentioned. The strategy of creating antibody fueled drugs is what can launch this company into something bigger than it already is. The creations made by Seattle Genetics can give this company the ability to grow into a pharmaceutical company. This is a goal that they have been aiming for since its founding almost 20 years ago.

Clay Siegall, the CEO of Seattle Genetics, plans for the company to grow into something more rather than having an even larger company buying it. Clay’s ambitions are evident due to his actions within the past few years. He now wants to focus more on drug marketing rather than development. This can be shown by the opening of a new office across seas to allow Seattle Genetics to handle international marketing. Along with this, Clay Seigall made the effort to acquire rights to a cancer-treating drug. His effort failed but still does show commitment to success.

In the past year, the valuation of Seattle Genetics has increased by more than 50 percent. Along with this, they have a list of 11 drugs available. The CEO of the company believes that at least 4 of these drugs has the ability to be sold worldwide. With these factors, Seattle Genetics is now moving closer to the goal of entering the pharmaceutical field.

Clay Siegall has a long track record of experience in cancer research and drug development. Prior to entering these fields, he attended George Washington University where he obtained a Ph.D. in Genetics. Along with this, he received a Bachelor’s degree in Zoology from the University of Maryland. In 1988, Clay joined the National Cancer Institute, National Institutes of Health and served there until 1991. From there he worked with the Bristol-Myers Squibb Pharmaceutical Research Institute until 1997. Upon leaving the company, Clay had co-founded Seattle Genetics.

Throughout his career, Clay Siegall has made several accomplishments. He has written over 60 scientific papers. Along with this, Clay holds 9 patents. His efforts in the field of science have been rewarded and recognized by several groups and organizations. These accomplishments prove that Clay has the ability to change the field of science.